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Osteopontin (OPN) is identified as a diagnostic and prognostic biomarker of tumor progression 
and metastasis. In non-small-cell lung cancer (NSCLC), the functions of OPN have not been well 
characterized. The current study sought to investigate the clinical implications of OPN expression in 
NSCLC and the role of OPN in the aggressiveness of the lung cancer cells. Using a proteomics approach, 
we identified that phospho-RON (p-RON) was one of the most remarkably up-regulated proteins 
in OPN-overexpressing cells. The levels of OPN and RON transcripts were unveiled as independent 
prognostic indicators of survival in nScLc (p = 0.001). Higher levels of OPN, RON and p-RON proteins 
were observed in tumor tissues. Knock down of the OPN gene suppressed the migration and invasion 
abilities of the A549 lung cancer cells which endogenously expresses OPN. While ectopic expression of 
OPN in the SK-MES-1 lung cancer cells increased levels of cellular invasion and migration. In addition, 
these changes were accompanied by a phosphorylated activation of RON. Small-molecule inhibition 
of RON or siRNA silencing of RON significantly reduced OPN-induced migration and invasion of lung 
cancer cells and had an inhibitory effect on the OPN-mediated cell epithelial-mesenchymal transition. 
Our study suggests that in NSCLC, the aberrant expression of OPN can be considered as an independent 
survival indicator and is associated with disease progression. OPN plays a crucial role in promoting 
migration and invasion properties of lung cancer cells through its phosphorylation activation of the 
RON signaling pathway, implying its potential as a therapeutic target in the treatment of NSCLC.
Lung cancer is one of the most prevalent and lethal cancers worldwide. Non-small-cell lung cancer (NSCLC) 
accounts for approximately 80–90% of all lung cancer1. The prognosis of NSCLC is poor and it is estimated that 
the 5-year survival rate for NSCLC is less than 20%2. High morbidity and mortality of NSCLC are mainly related 
to the high-frequency of metastasis. Therefore, it is crucial to find the major contributors to tumor metastasis and 
elucidate their molecular mechanisms involved in NSCLC progression in order to identify new targets for the 
development of anti-tumor therapies and prevention strategies.
Osteopontin (OPN) is an extracellular matrix phosphoprotein secreted by a number of cell types and is impli-
cated in a variety of biological functions including cell adhesion, migration, immune response, bone calcification 
and tumor progression3–5. It has been reported that the level of OPN correlates with tumor grade and progno-
sis in patients with the bladder, breast, prostate, and colon cancers6–8. Therefore OPN has been considered as 
a biomarker for tumor progression in many human tumors9–11. In NSCLC, evidence of OPN oncogenicity is 
sparse. It has recently been shown that elevated OPN levels in tumors and serum are associated with malignant 
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neoplasia12–14. Also NSCLC cell lines that natively express OPN have greater metastatic potential and invasive 
behavior5,15, but the molecular pathways for OPN during tumorigenicity are otherwise not understood.
Recepteur d’Origine Nantais (RON), also known as the macrophage stimulating 1 receptor (MST1R), is mainly 
expressed in macrophages, osteoclasts, hematopoietic and epithelial cells16–19. As one member of the receptor 
tyrosine kinase (RTK) family, RON is involved in a series of biological functions such as immune response and 
wound healing20,21. Aberrant expression of RON is associated with tumor stage, poor prognosis and invasiveness 
in many cancer types22. It is known that RON functions as a mediator of tumor progression in some cancers23,24. 
Once activated by its ligand, macrophage-stimulating protein (MSP), RON promotes the invasive growth of can-
cer cells mainly through activation of several signaling pathways such as β-catenin, PLCγ, PI3K/AKT and MAPK 
etc.25–27. RON also plays a role in immunosuppression by regulating the properties of tumor-associated mac-
rophages in the tumor microenvironment28. RON is highly expressed by osteoclasts and has been shown to par-
ticipate in bone metastasis through mediating dysregulated bone absorption29. It is also known that the functions 
of RON in cells can be independent of MSP30. In lung cancer, recent studies indicate that RON may be a potent 
biomarker of tumor progression, metastasis and prognosis31. To date, however, the potential biological roles of 
RON in the tumorigenesis of NSCLC and downstream pathways have not been fully elucidated.
The current study sought to investigate the expression levels of OPN protein in tissues from surgical patients 
with NSCLC and to evaluate the association of this molecule with clinical features and outcome. We also exam-
ined the in vitro biological functions of OPN in human lung cancer cell lines (namely A549 and SK-MES-1) after 
gene knockdown and ectopic expression, respectively. Our protein microarray analysis data established the link 
between OPN expression and the activation of RON in lung cancer cells, which led us to further investigate the 
combined prognostic value of RON and the regulation of RON signaling pathways by OPN in the aggressiveness 
of NSCLC cells.
Methods
Human lung cancer specimens. For gene expression profile analysis, we obtained a cohort of lung cancer 
patients with long-term follow-up from Peking University Cancer Hospital from 2003 to 2011. The study was 
approved by local ethics committees (Peking University Cancer Hospital and Xuanwu Hospital of Capital Medical 
University Ethics Committees) and performed in accordance with guidelines established by the World Medical 
Association Declaration of Helsinki. Written consent was obtained from all patients.
We obtained seventy seven paired tumor and adjacent normal tissues from this cohort (n = 77). Clinical infor-
mation of the patients for gene expression analysis is summarized in Table 1. The gene expression data from 
the cohort were analyzed after normalization using glyceraldehyde-3-phosphate desidrogenase (GAPDH) as an 
internal control.
For immunohistochemical (IHC) analysis, fresh frozen NSCLC tumor and paired adjacent normal tissues 
were obtained from twenty patients who received curative resection in Xuanwu Hospital of Capital Medical 
University from December 2011 to May 2014 (n = 20). These tissues were collected immediately after surgi-
cal resection and stored in the Tissue Bank of Cancer Institute of Capital Medical University. Ethical approval 
was provided by the Xuanwu Hospital of Capital Medical University Ethics Committees. Written consent was 
obtained from all patients.
IHC staining. Frozen sections of NSCLC (n = 20) and paired adjacent normal lung tissues (n = 20) were cut 
at a thickness of 4 μm using a cryostat. The sections were first fixed with 4% paraformaldehyde. Endogenous 
peroxidase activity was blocked with 3% hydrogen peroxide for 30 min. Sections were incubated for 30 min in 5% 
goat serum albumin blocking solution and probed with monoclonal mouse anti-OPN primary antibody (1:200) 
(ab8448, Abcam, Cambridge, UK), rabbit anti-p-Ron (Tyr1238/Tyr1239) (1:200) (sc-22193, Santa Cruz, CA, 
USA), and rabbit anti-RON (EP1132Y)(1:200) (ab52927, Abcam, Cambridge, UK). A peroxidase conjugated goat 
anti-mouse immunoglobulin IgG was purchased from ZSGB Biotechnology (Beijing, China). The diaminoben-
zidine (DAB) chromogen (Cell Signal Technology, Danvers, MA, USA) was used for the coloration. Finally, the 
sections were observed under a microscope (BX43, Olympus, Tokyo, Japan).
For data analysis, slides from all 20 pairs of the specimens were analyzed independently by two observers 
using light microscopy. The percentage of carcinoma cells with cytoplasmic/membranous/nuclear staining was 
recorded and a total of 5 microscopic fields were randomly selected and captured. Staining for OPN was evalu-
ated with Image-Pro Plus (IPP) v6.0 software (Media Cybernetics, USA). The strength of protein expression was 
calculated by the formulation of the IOD (Integrated option density)/Area.
Plasmids and chemical reagents. The OPN cDNA was cloned into a GV147 vector by Genechem Co., Ltd. 
(Shanghai, China) to establish the OPN expression construct. The shRNA plasmid targeting OPN was constructed 
by Genechem using a GV248 vector and the targeting sequence is CCTGTGCCATACCAGTTAA. RON-targeting 
siRNA duplexes of 5′-GGAGUACUAUAGUGUUCAA-3′ and 5′-CCUGCUGGACACACUAAUUTT-3′ were 
purchased from Genepharma (Suzhou, China). A scrambled siRNA 5′-AAUUAGUGUGUCCAGCAGGTT-3′ 
was used as the siRNA control. MK8033, a novel and specific dual ATP competitive c–Met/Ron inhibitor, was 
obtained from MedChemExpress (MCE, New Jersey, USA).
Reverse transcription-polymerase chain reaction (RT-PCR). RNA extraction, reverse transcrip-
tion (RT) and polymerase chain reaction were performed as described previously32. The pair of primers used 
for examining mRNA expression of OPN by PCR were 5′-TTGCAGTGATTTGCTTTTGC-3′ (sense) and 
5′-GTCAATGGAGTCCTGGCTGT-3′ (antisense). PCR was performed under the following conditions: an ini-
tial denaturation at 94 °C for 15 seconds; 30 cycles of denaturation at 95 °C for 30 seconds, annealing at 58 °C 
3Scientific RepoRtS |         (2019) 9:18101  | https://doi.org/10.1038/s41598-019-54843-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
for 30 seconds, and extension at 72 °C for 30 seconds; and a final extension at 72 °C for 5 minutes. A 305 bp PCR 
product was analyzed by Tris-acetate EDTA agarose (1% w/v) gel electrophoresis.
Quantitative analysis of OPN and RON gene transcripts in lung tissues. Levels of gene transcripts 
for OPN and RON were determined using quantitative RT-PCR in a qPCR thermocycler (BioRad Icycler IQ5). 
The detection system was based on the Amplifluor UniprimerTM probe system, in which a FAM-tagged universal 
probe was used (Millipore, England). The primers for the gene transcripts were designed in such a way that each 
primer sits in a unique region of the gene target and in two separate exons. A Z-sequence (5′ actgaacctgaccgtaca 
3′) was added to one of the primers and worked with the Universal probe to allow the formation of FAM-tagged 
amplicons. GAPDH gene transcripts were also quantified in the same cohort and used for the normalization. 
The primer pairs used for the respective gene transcripts were as follows: OPN (5′ agaagcagaatctcctagcc 3′ and 5′ 
actgaacctgaccgtacacatggtcatcatcatcttca 3′); RON (5′ catccacccagtgccaac 3′ and 5′ actgaacctgaccgtacaccacacagt-
cagccacag 3′); and GAPDH (5′ ctgagtacgtcgtggagtc 3′ and 5′ actgaacctgaccgtacacagagatgatgacccttttg 3′).
Cell culture and transfection. Human lung adenocarcinoma A549 cells and squamous SK-MES-1 cells 
were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were routinely 
cultured with Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal calf serum and 1× 
antibiotics. Cells were transfected with plasmids and siRNA by using Lipofectamine 3000 transfection reagent 
(L3000015, Invitrogen, USA). Stably transfected cells were selected by G418 for OPN overexpression or puro-
mycin for OPN shRNA knockdown. After two weeks, we established the stable OPN-overexpressing/OPN-low 
expressing cell lines.
Characteristic Number
(a)
Type
Tumour 77
Normal 77
Histology
Squamous 30
Adenocarcinoma 41
Small cell carcinoma 3
others 3
Tumour staging
T-1 9
T-2 43
T-3 13
T-4 12
Node status
N-0 36
N-1 15
N-2 26
Metastasis
M-0 77
M-1 0
TNM
TNM1 24
TNM2 18
TNM3 35
TNM4 0
Smoking history
No smoking 27
Smoking 50
Parameter F value p value
(b)
Differentiation 0.240 0.626
Embolism 0.000 0.993
Pleural invasion 0.170 0.682
T-stage 3.861 0.054
N-stage 9.277 0.004
TNM stage 8.098 0.06
Bone involvement 0.048 0.827
Smoking 0.532 0.469
OPN 11.620 0.001
RON 13.498 0.001
Table 1. Expression of OPN and RON genes in tissue from lung cancer patients. (a) The clinicopathological 
parameters of the lung cancer cohort for gene expression profiling. (b) Multivariate analysis of 
clinicopathological factors influencing overall survival.
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Western blotting and antibodies. Western blotting was performed as described previously33. Briefly, 
cells were cultured and collected, and then lysed in a lysis buffer (NaCl 150 mM, Tris 50 mM, Sodium azide 
0.02%, Sodium deoxycholate 0.5%, Triton X-100 1.5%, Aprotinin 1 μg/ml, Na3VO4 5 mM, Leupeptin 1 μg/ml, 
PMSF 100 μg/ml, SDS 0.1%, DTT 100 μM). Equal amounts of protein were separated by SDS-PAGE and blotted 
onto PVDF membranes. The membrane was then probed with the respective primary antibodies and corre-
sponding secondary antibodies. Anti-OPN, anti-RON (EP1132Y), anti-E-Cadherin, anti-N-Cadherin, anti-Twist 
and anti-β-Catenin antibodies were purchased from Abcam (Cambridge, UK). Anti-Slug, anti- Snail and 
anti-GAPDH antibodies were from Santa Cruz Biotechnology (California, USA). The human phospho-MSPR/
Ron (Y1238/Y1239) antibody was from R&D Systems (Minnesota, USA). The blotted proteins were then detected 
with a Z-ECL chemiluminescence kit (Luminata Forte; Millipore, Hertfordshire, UK) and photographed using 
the G-Box gel documentation system (Syngene, Cambridge, UK).
Scratch wound-healing migration assay. Cells were seeded to a 24-well plate to form a monolayer. 
Pipette tips were then used to scratch a line on the monolayer of each well. The gaps were captured under an 
inverted microscope at each time point as indicated during the incubation period. The distance of gap closure as 
a consequence of cellular migration was measured using ImageJ software (National Institutes of Health, http://
rsbweb.nih.gov/ij/).
Cell invasion assay. Transwell chambers, equipped with a 6.5 mm diameter polycarbonate filter insert 
(pore size 8 μm) (Becton Dickinson, Labware, Oxford, UK), were pre-coated with 50 μg/insert of Matrigel. Cells 
were seeded at a density of 2 × 104 cells/insert. After incubation for 48 hours, the cells that invaded through the 
Matrigel were quantified using a crystal violet staining assay (Sigma-Aldrich).
Electrical cell impedance sensing (ECIS) based cell migration assay. This method has been widely 
implemented by our laboratories and was outlined previously34. Briefly, 96-well W96E1 microarrays were used on 
the ECIS®Zθ (theta) instrument (Applied Biophysics Ltd, Troy, New Jersey, USA). Lung cancer cells were added 
to the wells of the array. Then confluent lung cancer monolayers in the arrays were electrically wounded (2000 
mA for 20 seconds each), after which the migration of the cells was immediately tracked over a range of frequen-
cies (1000–64000 Hz). All the experiments were conducted in triplicate. And the initial resistance reading of the 
SKMES-1 and A549 stable cell lines by the ECIS system was shown in Supporting Information Fig. S1.
Kinex antibody microarray. At the end of the treatment as indicated, lung cancer cells in T75 flasks were 
washed twice in ice-cold PBS and then sonicated in standard Kinex lysis buffer (20 mM MOPS, 1% Triton X-100, 
2 mM EGTA, 5 mM EDTA, 30 mM NaF, 60 mM β-glycerophosphate, 20 mM sodium pyrophosphate, 1 mM 
Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 1× complete protease inhibitor mixture (Roche Applied Science), 
1 mM DTT). The protein concentration was then quantified using fluorescamine protein-dye and the bovine 
serum albumin (BSA) was used as a standard. Approximately 100 μg of lysate protein samples were shipped in 
dry ice to Kinexus Bioinformatics Corporation (Vancouver, Canada) for Kinex™ KAM-880 Antibody Microarray 
service with 60% pan-specific antibodies and 40% phospho-specificantibodies. For the analysis of the Kinex pro-
tein microarray data, the normalized signal strength of protein isoforms and Z-ratio of sample comparison was 
used to identify the regulated candidate proteins. Z ratios were calculated by the division of the z-score difference 
from two groups by the standard deviation of the difference, and used as an indicator of differential expression of 
individual proteins in the group of OPN-overexpressing cells (threshold >1.5 or <−1.5).
Statistical analysis. SPSS version 19.0 (SPSS, Inc., Chicago, IL, USA) was used for statistical analyses. The 
association of expression with clinical features was analyzed using the Mann-Whitney U test. The IHC results 
were assessed using the paired t-test. The Student’s t-test was used to analyze the cell functions with two groups, 
while the analysis of variance (ANOVA) was used to compare the data of multiple groups. A p-value < 0.05 was 
defined as statistically significant.
Ethics approval and consent to participate. The study protocol was approved respectively by both 
Peking University Cancer Hospital and Xuanwu Hospital of Capital Medical University Ethics Committees. All of 
the participants signed an informed consent form.
Results
The expression level of RON has prognostic value as significant as that of OPN in patients with 
NSCLC. To investigate the association of transcription level of the OPN with patient survival in lung cancer, 
we performed gene expression profile analysis in a lung cancer patient cohort which included 77 pairs of tissues, 
namely tumor tissues and adjacent normal lung tissues (Table 1a). As shown in Fig. 1a, Kaplan-Meier survival 
analysis indicated that poorer patient survival was associated with higher expression of the OPN gene (p = 0.008). 
In the same cohort, as shown in Fig. 1b, poor patient survival was positively associated with elevated expression 
of the RON gene (p = 0.011). Multivariate analysis of clinicopathological factors influencing overall survival sug-
gested that RON, like OPN, was also an independent factor to predict overall survival of patients (p = 0.001), in 
line with the T-, N- or TNM stage (Table 1b). By IHC, our data indicated that higher levels of OPN, RON and 
p-RON (Y1238 + Y1239) were expressed in the NSCLC tissues compared with the paired adjacent normal tissues 
(p < 0.01, respectively) (Fig. 1c). In addition, RON and p-RON were mainly located on lung epithelial cell mem-
branes and cytoplasm in adjacent normal tissues, while in cancer tissues, their expressions were mainly detected 
in the cytoplasm of lung cancer cells.
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OPN promoted the phosphorylated activation of RON in NSCLC. We then established the OPN 
overexpression stable cell lines using SK-MES-1 cells which have a relatively low level of endogenous OPN expres-
sion (Supporting Information Fig. S2). The stable cell lines were subjected to sequential validation using RT-PCR 
(Fig. 2a) and Western blot (Fig. 2b) following puromycin selection for two weeks. To explore the molecular 
mechanism of OPN effects in lung cancer cells, the Kinex protein microarray analysis was utilized to compare 
the signaling proteomics of OPN-overexpression and the control of SK-MES-1 cells. As shown in Fig. 2c, fol-
lowing ectopic overexpression of OPN in SK-MES-1 cells, fifteen proteins were identified to be altered signifi-
cantly according to their Z-ratios. Based on this outcome, we found that phospho-RON (p-RON) was one of the 
most remarkably up-regulated proteins in OPN-overexpressing SK-MES-1 cells. In additional, the data from this 
Figure 1. Association of OPN expression and RON activation in NSCLC. (a) The cumulative survival of lung 
cancer patients is positively associated with the expression of OPN. (b) The cumulative survival of lung cancer 
patients is positively associated with the expression of RON. (c) Representative images of IHC staining with 
OPN, RON and p-RON (Y1238 + Y1239), respectively, in NSCLC tissue sections, compared with matched 
adjacent normal tissue sections (SP × 200). (d) IHC staining respectively revealed the positive expression of 
OPN, RON and p-RON (Y1238 + Y1239) in NSCLC tissue sections, compared with matched adjacent normal 
tissue sections (n = 20).
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protein microarray analysis enabled us to elucidate the levels of the RON-related signaling pathway checkpoint 
proteins as shown in Fig. 2d.
Effects of OPN overexpression and knockdown on in vitro functions of NSCLC cell lines. Major 
malignant phenotypes of cancer cells including cell invasion and migration were evaluated first. As shown in 
Fig. 3a, ectopic overexpression of OPN promoted the transwell invasion of SK-MES-1 cells (p < 0.01). On the other 
Figure 2. Profile analysis of signaling proteins in OPN-overexpression and control SK-MES-1 cells with the 
Kinex antibody microarray. (a) Verification of OPN overexpression in SK-MES-1 cells at a mRNA level by 
RT-PCR. (b) Verification of OPN overexpression in SK-MES-1 cells at a protein level by Western blotting. 
Western blotting developed using different antibodies or gels were sepreated by white space. (c) Lead proteins 
with significant change (at least Z ratio ± 1.5) in OPN-overexpressed SK-MES-1 cells were identified by the 
Kinex antibody microarray. (d) Profile of the RON-related signaling pathway proteins determined by the Kinex 
antibody microarray. Briefly, the signaling protein profiles of the cell lysate samples (labled as Vector and OPN-ex) 
were analyzed using the Kinex™ KAM-880 Antibody Microarray service Kinexus Bioinformatics Corporation 
(Vancouver, Canada) with 60% pan-specific antibodies and 40% phospho-specificantibodies. The expression level 
data are presented as globally-normalized signal strength of each individual protein isoforms in each sample. For 
fold change determination, Z Scores are calculated first by transforming the background-corrected spot intensity 
values for individual proteins after converting the globally-normalized mean to zero. As the transformation of 
z-scores is done before sample-to-sample comparison, it is therefore comparison-independent. Z ratios were then 
calculated by the division of the z-score differences of the two samples (i.e. OPN-ex substracted from Vector) by 
the standard deviation (SD) of all the differences for the comparision. The values of z ratios are presented as the 
level changes of individual proteins between the control and treated samples.
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hand, after transfection of the OPN-shRNA transgene into A549 cells with endogenous high OPN expression, the 
invasion property of A549 cells was significantly reduced (p < 0.01) (Fig. 3b). In addition, Ectopic overexpression 
of OPN in SK-MES-1 cells showed a remarkable increase in post-wound migration as indicated by the ECIS system 
and scratch wound-healing assay (p < 0.01, respectively) (Fig. 3c,e). In contrast, the knockdown of OPN expression 
resulted in a remarkable reduction in the migration ability of A549 cells (p < 0.01, respectively) (Fig. 3d,f).
The altered EMT related gene expression profile by OPN was dependent on the phosphoryla-
tion and activation of RON. We then investigated whether OPN could promote the phosphorylated activa-
tion of RON in NSCLC using Western blotting. As shown in Fig. 4a,b, compared with those of the control groups, 
the levels of RON and p-RON were significantly increased in the OPN-expressing A549 cells but decreased after 
knockdown of OPN expression. E-cadherin gene, the typical epithelial-to-mesenchymal transition (EMT) molec-
ular marker, was significantly downregulated in OPN-overexpressed A549 cells. Accordingly, another four typical 
EMT molecular markers (N-cadherin, β-catenin, Slug, and Twist) were upregulated in the OPN-overexpressed 
A549 cells (Fig. 4c). Knockdown of RON reversed the OPN-induced downregulation of E-cadherin and upreg-
ulation of N-cadherin, β-catenin, Slug and Twist (Fig. 4d). These results indicated that the promotion effects 
of OPN on cell migration and subsequent invasive abilities could be due to OPN-induced cell EMT which was 
dependent on the phosphorylated activation of RON signaling.
The colocalization and interaction between OPN and RON in NSCLC cells. To visualize the dis-
tribution of OPN and RON in NSCLC, we performed the multi-colour immunofluorescence using NSCLC tissue 
sections. As shown in Fig. 5a, OPN was mainly located in the cytoplasm, while RON was stained both in the cyto-
plasm and membrane. Their co-localization was observed in the cytoplasm and strengthened with the increased 
distribution of RON in the cytoplasm of tumour cells. We further performed CO-IP assay in order to evaluate the 
interaction between OPN and RON proteins. As shown in Fig. 5b, RON was indeed pulled down together with 
OPN by the OPN antibody in A549 cells, whereas none of these two proteins was recovered when an irrelevant 
antibody (IgG) was used for IP, thus establishing the specificity of the assays. The Co-IP result indicated that there 
was physical interaction between OPN and RON in A549 cells.
Secreted opn promoted the malignant phenotypes of lung cancer cells through the medi-
ation of the RON signaling pathway. An antibody neutralization assay was carried out in order to 
explore whether OPN-induced cell migration and invasion were mainly caused by secreted OPN. We supple-
mented OPN-neutralizing antibody and IgG-neutralizing antibody respectively to the media of the cultured 
OPN-overexpressing A549 cell line. As shown in Fig. 6a, The OPN-neutralizing antibody inhibited cell invasion 
by over 40% in OPN-overexpressing A549 cells, compared to the control groups with an IgG-neutralizing anti-
body in medium (p < 0.001). Likewise, the OPN-neutralizing antibody also inhibited cell migration by over 50% 
in OPN-overexpressing A549 cells compared to the IgG control (p < 0.01) (Fig. 6b). In order to further explore 
the influence of the RON signaling pathway on cell migration and invasion induced by OPN, we conducted 
the experiments with RON knockdown and exposure of the cells to MK803, a novel and specific Ron inhibitor. 
Compared to the control group, the invasion and migration of A549 cells in the OPN overexpression group were 
significantly enhanced, respectively (p < 0.001). However, after the addition of MK803, the invasion and migra-
tion abilities of the OPN-overexpressing A549 cells were significantly reduced, respectively (Fig. 6c,d. p < 0.001). 
Knockdown of RON by gene silencing also significantly reduced cell invasion (Fig. 6e) and the post-wound 
migration (Fig. 6f) capacity of OPN-overexpressing A549 cells (p < 0.001, respectively).
As the level of OPN expressin in the wild-type A549 cell line is intermediate, to verify the effect of secreted 
OPN in coniditoned medium on aggressiveness of lung cancer cells, we further conducted new assays in the pres-
ence of the tumor conditioned medium from the stable SK-MES-1 cell line with OPN overexpression. As shown 
in Supporting Information Fig. S3, after OPN overexpression, both the overexpression of OPN in cells (OPNex) 
and the conditioned medium (OPN CM) from the OPNex cells promoted the cellular invasion and migration 
(p < 0.001 vs con CM, respectively). However, when the RON inhibitor MK8033 (RONi) or the si-RON (RONkd1 
and RONkd2) were applied, the induced cell migration and invasion by the secreted-OPN containing CM were 
eliminated in the SK-MES-1 cell line. The presence of OPN protein in the conditioned medium was confirmed 
by Western blot while several albumin/MMP-cleaved fragments of OPN protein in medium can also be observed 
(Supporting Information Fig. S4) as reported elsewhere35,36.
Discussion
OPN is one of the known proteins considered to be associated with tumor genesis and progression in malignan-
cies. It has been reported that OPN expression is upregulated in a variety of human carcinomas, including breast, 
prostate, lung and melanoma. And the expression levels of OPN are often closely related to clinical outcomes in 
cancer patients37. In the current study, we have shown that OPN is frequently over-expressed in both NSCLC 
tissue and plasma (Supporting information Table S1) which are mirrored well with each other. These findings 
support that OPN is a valuable indicator for diagnosis and prognosis in NSCLC patients. This is supported by 
previous studies which show that the elevated level of OPN plasma level in patients with NSCLC are reduced after 
resection or following platinum-based chemotherapy, but seem to upturn with recurrence38,39.
In order to further characterize this biomarker, we focus on the roles of OPN in the mediation of the malig-
nant phenotype of NSCLC cells. Our results provide evidence that over-expression of OPN is linked to the ele-
vation of invasion and migration of SK-MES-1 cells in vitro. In contrast, following genetic silencing of OPN, the 
properties of cellular invasion and migration in A549 cells are reduced. These results suggest a positive role of 
OPN in the aggressiveness of lung cancer cells.
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Figure 3. Effect of OPN expression level on the aggressive property of NSCLC cells. (a) A significant increase 
of in vitro Matrigel invasion in OPN-overexpressing SK-MES-1 cells. (b) Knockdown of OPN in A549 cells 
significantly reduced cellular Matrigel invasion. (c) OPN overexpression in SK-MES-1 cells increased cellular 
migration when assessed using ECIS after electric wounding (red dotted line), as indicated by resistance. (d) 
Knockdown of OPN markedly inhibited the post-wound migration capacity of A549 cells in the ECIS system 
which showed decreased resistance. (e) OPN overexpression in SK-MES-1 cells increased migration capacity 
after cultivation for 24 hours. (f) Knockdown of OPN significantly reduced cellular migration capacity of A549 
cells. The results represent the mean values ± SD of three independent experiments. *p < 0.05, **p < 0.01.
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NSCLC cell lines that natively express OPN have greater metastatic potential and invasive behaviour, but the 
molecular pathways for OPN during tumorigenicity are otherwise not understood. Our protein microarray study 
shows that RON and p-RON are both significantly increased in OPN-overexpressing SK-MES-1 cells. IHC results 
suggest that expression levels of OPN, RON and p-RON are dramatically elevated in NSCLC tissue when com-
pared with paired adjacent normal tissue. Western blotting results also indicate that the levels of RON and p-RON 
are significantly increased in the OPN-expressing A549 cells but significantly decreased following OPN knock-
down. Therefore, RON may play a vital role in participating in OPN-mediated tumorigenicity in lung cancer cells.
RON is a RTK belonging to the MET RTK family40. The specific ligand for RON is MSP, which is also known 
as HGF like protein (HGFL)41. Multiple mechanisms of aberrant RON signaling have been described previously. 
Classically, MSP binding to RON causes receptor tyrosine phosphorylation leading to up-regulation of RON cata-
lytic activity and subsequent activation of downstream signaling molecules42. Alternatively, RON can be activated 
through other receptors by MSP-independent mechanisms19. Recent investigations have shown that the function 
of RTKs can be regulated by integrin-dependent cell adhesion to extracellular matrix (ECM) in the absence of a 
ligand43. ECM-induced integrin aggregation may lead to RON oligomerization and transphosphorylation, which 
depend on the kinase activity of RON itself. OPN, also known as an important member of the matricellular pro-
tein family, can bind integrins through the arginine-glycine-aspartate (RGD) domain44,45. Therefore, we speculate 
that the physical interaction between OPN and RON may be in a MSP-independent manner and is possibly 
mediated by integrins.
Kaplan-Meier survival analysis and multivariate analysis of clinicopathological factors suggest that the RON 
transcript expression, like OPN, is also an independent factor to predict the overall survival of patients. Increased 
RON expression is also found in OPN-overexpressing NSCLC tissues and cells. Therefore, it is possible that 
OPN induces the transcript expression of RON, and then elevates the level of p-RON. In seeking the relevance 
of the current findings, the putative transcription factor binding sites (TFBS) in RON promoter sequence have 
Figure 4. Alteration of the EMT-related protein levels by OPN was dependent on the phosphorylated activation 
of RON. (a,b) The levels of total RON and p-RON (Y1238 + Y1239) proteins were significantly increased in 
OPN-overexpressed A549 cells but decreased in A549 cells which were treated with OPN shRNA, as indicated 
by western blotting. (c,d) The expression of OPN, RON and EMT markers (E-cadherin, N-cadherin, β-catenin, 
Slug, Twist) in A549 cells. OPN downregulated E-cadherin expression and upregulated the expression of 
N-cadherin, β-catenin, Slug, Twist. The OPN-induced differential expression of the EMT markers was reversed 
following the knockdown of RON by siRNA1 and siRNA2. Western blotting developed using different 
antibodies or gels were sepreated by white space.
1 0Scientific RepoRtS |         (2019) 9:18101  | https://doi.org/10.1038/s41598-019-54843-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
been identified in the Alggen–promo database (http://alggen.lsi.upc.es). In total 24 transcription factors are pre-
dicted to bind the RON promoter sequence and regulate transcription of the RON gene (Supporting Information 
Fig. S5). Several of them have been reported to be involved in the OPN regulated signal networks, such as NF-146, 
p5347 and Sp148.
Figure 5. Co-localization and interaction of OPN and RON proteins. (a) OPN (shown in green) and RON 
(shown in red) were probed in lung carcinoma and matched adjacent normal tissue. Nuclei were stained with 
Hoechst dye 33258. Co-localization was investigated by confocal microscopy. (b) Immunoprecipitation (IP) 
of OPN from whole cell lysate of A549 cells. An irrelevant IgG was used as a control of the anti-OPN antibody 
during IP. Immunoprecipitated proteins and the whole cell lysate were then analyzed by western blotting. 
Western blotting developed using different antibodies or gels were sepreated by white space.
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Figure 6. Secreted OPN promoted the malignant phenotypes of lung cancer cells mediated by the RON 
signaling pathway. (a,b) Functions of the OPN-overexpressing A549 cells including invasion and migration, 
respectively, were dramatically inhibited in the presence of OPN-neutralizing antibody (OPN-Ab) respectively 
compared to IgG-neutralizing antibody (IgG-Ab) control groups (p < 0.01). OPN-overexpressing A549 cells 
were treated with media containing 20 μg/ml of OPN-Ab and IgG-Ab, respectively, to block the secreted OPN 
protein. (c,d) The elevated levels of invasion and migration A549 cells by OPN overexpression were abolished 
after cells were exposed to 10 μM of the RON inhibitor MK8033 (RONi) for 24 hours compared to the control 
groups (p < 0.001). (e,f) knockdown of RON by siRNA (kd1 and kd2, respectively) in OPN overexpressing A549 
cells significantly reduced the invasion and migration capacities of the cells, respectively. The results represent 
the mean values ± SD. **p < 0.01, ***p < 0.001.
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Our data confirm that the expression of OPN can induce RON receptor tyrosine phosphorylation, which 
could induce the subsequent activation of downstream signaling cascade molecules such as Catenin, ERK, Smad 
and NFκB and promote malignant phenotypes of lung cancer cells (schematically illustrated in Fig. 7). It has been 
reported that MSP-induced EMT relies on the phosphorylation and activation of RON and Erk1/243. We show 
here that small molecule inhibition or gene silencing of RON significantly reduces OPN- overexpression-induced 
migration and invasion of lung cancer cells, and inhibits the OPN-induced cell EMT. This suggests that the RON 
signaling pathway participates in the OPN-induced malignant properties through mediating the EMT program 
in lung cancer cells. To the best of our knowledge, this is the first report describing the regulation of OPN on RON 
in lung cancer cells. Herein we provide evidence indicating the potential biological roles of OPN and RON in 
the progression of NSCLC, it might be interesting to further investigate the therapeutic potential of targeting the 
OPN/RON downstream signaling pathways in NSLC.
conclusion
In conclusion, our data indicate that higher levels of OPN are associated with poorer patient outcome in NSCLC. 
This study demonstrates for the first time that OPN exerts oncogenic functions in lung cancer cells through the 
modulation of the activated phosphorylation of RON. Inhibition of RON activity may provide therapeutic advan-
tages for blocking OPN-promoted malignant phenotypes of cancer cells including migration, invasion and EMT. 
All these findings lay the foundation for the possible clinical application of OPN and RON, not only as biomarkers 
for diagnostic and prognostic purposes, but also as potential therapeutic targets in NSCLC.
Novelty and impact. The clinical significance and molecular role of OPN in the progression of 
non-small-cell lung cancer (NSCLC) have not been well characterized. Here, the authors provide evidence that 
OPN and RON are both independent indicators of patient survival. They further find that OPN plays a crucial 
role in promoting aggresiveness of lung cancer cells through its phosphorylation activation of the RON signaling 
pathway, implying its potential as a therapeutic target in the treatment of NSCLC.
Data availability
The datasets used and/or analysed during the current study are available from the corresponding author on 
reasonable request.
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Figure 7. Schematic illustration of molecular mechanisms underlying the aggressiveness induced by the 
protein-protein interaction of OPN and RON in lung cancer cells. The changes of the relevant signaling check-
point proteins were identified by the Kinex antibody array.
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